Ben Towne Center for Childhood Cancer Research
Accelerating Progress Toward Cures
Fine-tuning CAR T-cell immunotherapy to benefit more kids – 12.11.2019 – On the Pulse
Seattle Children’s researchers are continuing to realize the promise of CAR T-cell immunotherapy and improve outcomes in difficult to treat pediatric cancers. They are applying knowledge gained from ongoing clinical trials to study effects on the youngest patients, develop new interventions to prevent side effects and boost T-cell persistence, and to better understand resistance to therapy. Research recently published in major scientific journals and presented at the 2019 American Society of Hematology (ASH) Annual Meeting contributes new insight guiding the evolution of the experimental therapy. On the Pulse spoke with Dr. Colleen Annesley, Dr. Rebecca Gardner and Dr. Rimas Orentas about their findings.
Seattle Children’s opens a ‘cure factory’ to explore treatments for childhood cancer and other diseases – 10.15.2019 – GeekWire
Seattle Children’s opened Building Cure, a new building in downtown Seattle that will act as a research hub to explore treatments for childhood cancer and other diseases. It’s a symbol of how far immunotherapy has come in the past decade, when Seattle Children’s made its first investment in the field. “We had no idea at that time that we would accelerate immunotherapy products the way we have and impact kids the way we have,” said Dr. Jim Hendricks, president of Seattle Children’s Research Institute. The building has a “cure factory,” where scientists will create cell-based therapies for up to 1,000 children each year. “This is where the transition happens from learning how to cure a childhood disease in a mouse or petri dish and beginning the very hard work of learning how to cure that disease in children,” said Dr. Mike Jensen, director of the Ben Towne Center for Childhood Cancer Research at Seattle Children’s.
Pediatric CAR T-cell immunotherapy trial aims to improve remission rates of leukemia at Children’s National Health System (This story appeared in over 60 news outlets) – Morningstar
Children's National Health System is opening a CAR T-cell immunotherapy trial, PLAT-05, which first launched at Seattle Children’s, for pediatric patients with relapsed positive acute lymphoblastic leukemia. Children’s National and Seattle Children's are both a part of CureWorks, an international collaborative of leading academic children's hospitals determined to accelerate the development of immunotherapy treatments for childhood cancer. "Extending the reach of this clinical trial not only allows patients to be treated in their own community, but it also helps to accelerate our ability to ultimately develop a treatment that enables all kids with cancer to grow up and realize their full potential,” said Dr. Mike Jensen, executive director of CureWorks and director of the Ben Towne Center for Childhood Cancer Research at Seattle Children's Research Institute.